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ABSTRACT
Background: Skin flap grafting is a popular approach for reconstruction of critical skin and underlying soft tissue 
injuries. In a previous study, we demonstrated the beneficial effects of two 5α-reductase inhibitors, azelaic acid and 
finasteride, on tissue survival in a rat model of skin flap grafting. In the current study, we investigated the 
involvement of nitric oxide and inducible nitric oxide synthase (iNOS) in graft survival mediated by these agents. 
Methods: A number of 42 male rats were randomly allocated into six groups: 1, normal saline topical application; 
2, azelaic acid (100 mg/flap); 3, finasteride (1 mg/flap); 4, injection of L-NG-nitroarginine methyl ester (L-NAME)
(i.p., 20 mg/kg); 5, L-NAME (20 mg/kg, i.p.) + azelaic acid (100 mg/flap, topical); 6, L-NAME (20 mg/kg, i.p.) +
finasteride (1 mg/flap, topical). Tissue survival, level of nitric oxide, and iNOS expression in groups were 
measured. Results: Our data revealed that azelaic acid and finasteride significantly increased the expression of
iNOS protein and nitric oxide (NO) levels in graft tissue (P < 0.05). These increases in iNOS expression and NO 
level were associated with higher survival of the graft tissue. Conclusion: It appears that alterations of the NO 
metabolism are implicated in the azelaic acid- and finasteride-mediated survival of the skin flaps. Iran. Biomed. J. 
19 (2): 111-116, 2015
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INTRODUCTION
kin flap grafting is indicated for reconstruction 
of massive deep skin damages and underlying 
soft tissue injuries [1]. It is the most popular 
surgical method for critical skin defects especially 
when there is a need for massive reconstruction of 
complex anatomic structures, such as covering an 
amputation stump or reconstruction of breast [2]. The 
success rate of grafting is limited by 
ischemia/reperfusion (I/R)-induced injury of the graft 
tissue. Studies have revealed that microcirculatory 
intravascular thrombosis causes the I/R-induced 
morbidity of the flap that decreases the success rate of 
the procedure [3, 4].
Various approaches have been used to improve the 
outcomes and reduce the morbidities resulting from I/R 
injury of skin flaps [5, 6]. In addition, several 
pharmacological agents have been tested in preclinical 
[7, 8] and clinical studies [9]. Hence, there is a need for 
intensive studies for understanding the drug targets and 
agents applicable for the treatment of this situation. 
Dihydrotestosterone (DHT) has long been recognized 
for its detrimental effects on ischemic events [10, 11]. 
It has been known that prevention of DHT biosynthesis 
may improve the outcomes of I/R injury in animal 
models. We previously demonstrated that DHT 
synthesis inhibitors, azelaic acid and finasteride,
preserve the skin flaps in rat models through reducing 
the apoptotic cell death of the skin flap [12]. Another 
study have also demonstrated DHT is responsible, at 
least in part, for the myocardial damage induced by I/R 
in male rats [13]. Beyond this, researchers have noted 
the vasoactive properties of DHT as a functional result 
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of its effect on inducible nitric oxide synthase (iNOS)
[14]. It is assumed that iNOS activation results in 
vasodilation and its local activation improve the blood 
supply of the affected tissue [15].  Thus, in the current 
study, we tried to investigate the potential involvement 
of nitric oxide (NO) metabolism in finasteride- and 
azelaic acid-induced survival of skin flaps in rat animal 
models. 
MATERIALS AND METHODS
Animals and ethical considerations. The study 
protocol was approved by Ethics Committee of the Iran 
University of Medical Sciences (Tehran, Iran). Male 
Sprague-Dawley rats (n = 42, weighing between 200
and 250 g), were chosen for random pattern cranial-
based skin flap elevation. The animals were kept in 
separate cages with free access to food and water. 
Experimental design. Experimental design, study 
groups, and surgical approaches to create models were 
according to our previous study [12]. Briefly,  animals 
were allocated into six experimental groups: 1, normal 
saline topical application; 2, azelaic acid (100 mg/flap, 
Merck, USA); 3, finasteride (1 mg/flap, Reddy, India); 
4, injection of L-NG-Nitroarginine methyl ester (L-
NAME, 20 mg/kg, i.p., Sigma, Germany); 5, L-NAME
(20 mg/kg, i.p.) + azelaic acid (100 mg/flap, topical); 
6, L-NAME (20 mg/kg, i.p.) + finasteride (1 mg/flap, 
topical). In the last two groups, L-NAME was injected 
30 minutes before azelaic acid or finasteride
application. Drugs were solubilized in 10% (v/v) 
ethanol in distilled water. The solvent had no effect on 
the parameters studied in the current research. 
Skin flap surgery and calculation of necrotic area. 
Method of surgical approach for creating skin flap 
models and calculation of necrotic area were 
performed based on the McFarlane's method [12].
Briefly, for calculating the necrotic area, photographs 
were taken from the flaps, and necrotic areas were 
measured by superimposition of photographs on a 
graph paper. The results were expressed as percentages 
of necrotic area and calculated as follows: the extent of 
necrotic area × 100/total area of the flap (viable and 
necrotic).
iNOS protein expression in flap tissue. Western-
blotting method was used to study the expression of 
iNOS protein in skin tissue of experimental groups. 
The protocol for preparation and Western-blot analysis 
of the samples were according to our previous 
experiment [12]. Rabbit anti-iNOS (1:200) and mouse 
anti-β-actin antibodies (both from Abcam, USA) were 
used in this study.
Measurement of nitrite/nitrate concentration in 
skin flaps. Preparation of tissue homogenate of skin 
flaps and control skin has been described previously 
[12]. Then the homogenate was centrifuged. After 
centrifugation, supernatant was removed and used to 
determine the levels of NO metabolites by assaying 
nitrite (NO2-) plus nitrate (NO3-) using the Nitric 
Oxide Colorimetric Assay Kit (Roche Applied Science, 
Indianapolis, IN, USA) according to the manufacturer's 
instruction. 
Statistical analysis. SPSS statistical package (v. 17, 
IBM Corporation, USA) was used to analyze the data. 
Since the data showed a normal distribution pattern 
using Kolmogorov-Smirnov test as well as 
homogeneity of variance, the results were statistically 
evaluated by one-way analysis of variance (ANOVA). 
ANOVA was used for comparison of flap survival, 
iNOS/β-actin expression, and nitrite/nitrate 
concentration among multiple groups, followed by 
Tukey test for intergroup comparisons. Quantitative 
data were presented as mean ± SEM, and P value less 
than 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
In the current study, we demonstrated that topical 
administration of azelaic acid or finasteride improved 
the surgical flap survival and decreased graft tissue 
necrosis in a male rat model (Fig. 1). In control group, 
mean flap necrotic area was 48.17% ± 2.22%, which 
was significantly decreased to 32.5% ± 02.55% and 
35.0% ± 1.59% (P < 0.05 vs. control group) after 
treatment by azelaic acid and finasteride, respectively. 
L-NAME by itself had no significant effect on flap 
Fig. 1. Effects of different type of treatments on skin flap 
survival. Data are shown as Mean ± Standard error of mean 
(SEM) of percent of necrotic area for each group. *P < 0.05 vs. 
control group, #P < 0.01 vs. azelaic acid, and †P < 0.001 vs. 
finasteride. No significant differences between L-NAME, L-
NAME+ Azela, L-NAME + Finas and the control group were 
observed. Azela, azelaic acid; Finas, finasteride.
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Fig. 2. Expression of iNOS in skin flaps obtained from different groups of treatment. Relative densities of bands were normalized 
to the density of corresponding bands for β-actin and values represent means  ± Standard error of mean (SEM) of each group. Upper 
panel illustrates a sample of iNOS and related β-actin expressions in each group. Lower panel shows the normalized values of iNOS/β-
actin expression ratio. *P < 0.05 and **P < 0.01 vs. control group, #P < 0.001 vs. azelaic acid and † P < 0.001 vs. finasteride. Azela: 
azelaic acid, Finas: finasteride.
necrosis (50% ± 2.75%, P > 0.05 vs. control group). 
However, in the animals treated with azelaic acid,
pre-treatment with L-NAME increased the average 
necrotic area to 48.0% ± 3.52% (P < 0.01), which was 
significant when compared to the group with azelaic 
acid only. Similarly, in the case of finasteride, pre-
treatment with L-NAME increased necrotic area (P <
0.001 vs. finasteride alone). These results presumably 
demonstrate the NO-dependent mechanism of effect of 
azelaic acid and finasteride on survival of surgical flap.
Treatment with azelaic acid or finasteride increased 
iNOS expression in skin tissue in comparison to 
control group (P < 0.01, Fig. 2). iNOS/β-actin ratio
was increased more than two-fold when skin flaps were 
treated with azelaic acid and finasteride. While it is 
reasonable to consider this increase of iNOS 
expression as a result of DHT synthesis inhibition, 
existing data on iNOS expression in response to DHT 
treatment from different studies are versatile. Gonzalez 
et al. [15] have noted the elevation of iNOS expression
level in cerebral artery endothelium following   ex vivo
DHT treatment. Bae et al. [16] have reported that in 
vivo treatment of rat vascular smooth muscle cells with 
DHT significantly decreased the iNOS protein 
expression. On the other hand, Kolasa et al. [17] have 
indicated that DHT can regulate the expression of 
iNOS, and finasteride-induced DHT deficiency 
upregulates iNOS expression [14].  
Surprisingly, treatment with L-NAME significantly 
decreased iNOS expression compared to the control 
group (P < 0.05). Moreover, pre-treatment with L-
NAME decreased iNOS expression in flaps treated 
with azelaic acid and finasteride compared to the 
control groups (P < 0.05) having azelaic acid- and 
finasteride-treated flaps alone (P < 0.001, Fig. 2). To
date, no direct effect of L-NAME on expression of 
iNOS has been reported. This effect of the agent 
observed here could be presumably attributed to the 
decreased infiltration of the tissue by leukocytes, the 
cells which are the main sources of iNOS [17]. In a 
study by Kane et al. [18], iNOS expression was mostly 
localized in mast cells gathered in angiogenic regions 
of the flap. These cells were detected to express 
vascular endothelial growth factor and basic fibroblast 
growth factor, which contribute to the angiogenesis in 
the ischemic tissue. Thus, azelaic acid and finasteride 
presumably induce NO-mediated angiogenesis in the 
flap tissue and improve survival flap. It is well 
established that agents with angiogenic activity could 
improve the outcomes in I/R injury in most tissues 
[19]. We recommend future investigations for 
determining the potential role of angiogenesis in 
improved surgical flap survival mediated by 5α-
reductase inhibitors, azelaic acid and finasteride.    
Figure 3 was taken from the skin flap of one of the 
rats of each group in which the distal part of the flaps 
in control and L-NAME-treated group demonstrated 
extended necrotic area compared to azelaic acid- or 
kDa
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Fig. 3. The effect of different types of treatments on necrosis of distal parts of skin flap seven days after surgery. Figures include a 
sample from each group. (A) The complete necrosis of distal sections in control group, (B) limited necrosis of skin flap in margins of 
distal parts in finasteride (1 mg/flap, topical application)-treated rats, (C) Decreased necrotic area of flap in topical azelaic acid (100
mg/flap)-treated group, (D) L-NAME (20 mg/kg, i.p.) treatment and extended necrotic area, (E) Pre-treatment with L-NAME in 
finasteride-treated rats with a large area of distal flap necrosis that has been expanded to the proximal parts, (F) complete necrosis of
distal part in L-NAME + azelaic acid-treated group.   
finasteride-treated rats. The latter two groups also 
showed a limited flap necrosis in the margins of distal 
part. This result further confirms the NO-dependent 
protective effects of azelaic acid and finasteride
treatment in surgical flaps. In control group, total 
content of NO metabolites was 14.6 ± 2.5 μmol/l tissue 
homogenate (Fig. 4). Treatment with azelaic acid and 
finasteride increased nitrite plus nitrate concentrations 
to 22.5 ± 3.1 μmol/l and 24.9 ± 3 μmol/l homogenate, 
respectively (P < 0.05). L-NAME blocked NO 
production and decreased NO metabolites to 2.73 ± 0.9
μmol/l (P < 0.01). Pre-treatment with L-NAME in 
azelaic acid and finasteride groups significantly 
decreased nitrite plus nitrate (4.61 ± 1.6 μmol/l and 
3.82 ± 1.1 μmol/l, respectively) in comparison to the 
control groups (P < 0.01), azelaic acid and finasteride-
treated groups alone (P < 0.001). It appears that azelaic 
acid and finasteride increase flap survival, at least in 
part, through induction of NO synthesis via iNOS. 
However, role of iNOS in protection against I/R injury 
is a matter of debate. While many studies have shown 
beneficial effects of iNOS elevation on the I/R injury
A
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Fig. 4. Concentration of NO metabolites in skin tissue 
homogenate prepared from the flap area. Data are represented as 
means ± standard error of mean (SEM) of each group. *P < 0.05
and **P < 0.01 vs. control group, #P < 0.001 vs. azelaic acid 
and † P < 0.001 vs. finasteride. Azela, azelaic acid; Finas, 
finasteride.
of the kidney [20, 21], skin [18] and retina [22], some 
others have reported its detrimental effects on skin [23]
and kidney [24].
Beyond the effects of azelaic acid and finasteride on 
NO activity of the injured tissue, their involvement in 
alteration of the balance of testosterone 5α-reduction 
and aromatization may play a role in flap tissue 
longevity. This result can be deduced from the fact that 
testosterone 5α-reduction and aromatization are 
implicated in better response of females to cerebro-
vascular and ischemic events [13]. In sum, the results 
unveiled the beneficial effect of 5α-reductase 
inhibitors, azelaic acid and finasteride, in surgical flap 
survival by alterations in NO and iNOS metabolisms. 
However, further investigations are required to exactly 
determine the mechanisms of surgical flap survival 
with these two drugs. 
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